StockTipsArenaBeta

BUY Piramal Pharma Limited — Kshitija Salvi, Globe Capital Market

BUYPiramal Pharma Limited
Piramal Pharma share price target & all analyst calls

byKshitija Salvi, Globe Capital MarketHorizon: NA (inferred Swing (≤2wk))7 Sept 2026via CNBC Awaaz.

Entry₹219.82Inferred
Target₹245
Total upside +11.45% (call closed)
Stop loss₹213-3.10% risk
Exit₹21310 Sept 2026, 3:05 pm
Stop-loss hit-3.10%
Follow Kshitija Salvi for new calls(14% target hit, 29 closed calls)Get alertsWatch PPLPHARMA for new buy/sell callsGet alertsSee 149 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 10 Sept 2026
4 supporting2 neutral1 opposing
Supports the BUY call (4)

Piramal Pharma CDMO Strategy Helps Clients Navigate US Tariff Risks

NewsGoogle News·5 Sept · 5d ago

(opens in new tab)

Piramal Pharma: अमेरिकी टैरिफ के खतरे के बीच कंपनी की नई स्ट्रैटेजी, मुनाफे में दमदार उछाल

NewsGoogle News·5 Sept · 5d ago

(opens in new tab)

Piramal Pharma Strengthens Future Ready Operations with 22.6% Emissions Reduction, 41% Renewable Energy and Zero USFDA OAI Observations

NewsGoogle News·26 Aug · 2w ago

(opens in new tab)

2 advisors have active short-term BUY calls on this stock

Advisor consensus · adjacent horizon·26 Aug · 2w ago

Neutral / worth noting (2)

US envoy Sergio Gor meets Piramal Group Chairman Ajay Piramal, discusses expansion plans in US

NewsGoogle News·27 Aug · 2w ago

(opens in new tab)

Piramal Pharma emphasises sustainability in FY 2025-26 report

NewsGoogle News·24 Aug · 2w ago

(opens in new tab)
Weighs against the BUY call (1)

Piramal Pharma reports 22.6% drop in Scope 1 & 2 emissions for FY26

NewsGoogle News·24 Aug · 2w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Piramal Pharma

All analyst calls on Piramal Pharma

More from Kshitija Salvi, Globe Capital Market

Every call and its outcome